|
1
|
Gimbrone MA, Leapman SB Jr, Cotran RS, et
al: Tumor dormancy in vivo by prevention of neovascularization. J
Exp Med. 136:261–276. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar
|
|
3
|
Folkman J: Angiogenesis: an organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brown LF, Detmar M, Claffey K, et al:
Vascular permeability factor/vascular endothelial growth factor: a
multifunctional angiogenic cytokine. EXS. 79:233–269.
1997.PubMed/NCBI
|
|
5
|
Herbert SP and Stainier DY: Molecular
control of endothelial cell behaviour during blood vessel
morphogenesis. Nat Rev Mol Cell Biol. 1:551–564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wells A: EGF receptor. Int J Biochem Cell
Biol. 31:637–643. 1999. View Article : Google Scholar
|
|
8
|
Ciardiello F and Tortora G: Epidermal
growth factor receptor (EGFR) as a target in cancer therapy:
understanding the role of receptor expression and other molecular
determinants that could influence the response to anti-EGFR drugs.
Eur J Cancer. 39:1348–1354. 2003. View Article : Google Scholar
|
|
9
|
Morelli MP, Cascone T, Troiani T, et al:
Anti-tumor activity of the combination of cetuximab, an anti-EGFR
blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and
EGFR tyrosine kinases. J Cell Physiol. 208:344–353. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar
|
|
11
|
Kerbel RS: Antiangiogenic therapy: a
universal chemosensitization strategy for cancer? Science.
312:1171–1175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dancey JE and Freidlin B: Targeting
epidermal growth factor receptor - are we missing the mark? Lancet.
362:62–64. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang JC, Haworth L, Sherry RM, et al: A
randomized trial of bevacizumab, an anti-vascular endothelial
growth factor antibody, for metastatic renal cancer. N Engl J Med.
349:427–434. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jain RK: Normalization of tumor
vasculature: an emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Li Z, Han Y, et al:
Nanoparticle-based delivery system for application of siRNA in
vivo. Curr Drug Metab. 11:182–196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oh YK and Park TG: siRNA delivery systems
for cancer treatment. Adv Drug Deliv Rev. 6:850–862. 2009.
|
|
18
|
Castanotto D and Rossi JJ: The promises
and pitfalls of RNA-interference-based therapeutics. Nature.
457:426–433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Urban-Klein B, Werth S, Abuharbeid S, et
al: RNAi-mediated gene-targeting through systemic application of
polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther.
12:461–466. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boussif O, Lezoualc’h F, Zanta MA, et al:
A versatile vector for gene and oligonucleotide transfer into cells
in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA.
92:7297–7301. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Franklin WA, Veve R, Hirsch FR, et al:
Epidermal growth factor receptor family in lung cancer and
premalignancy. Semin Oncol. 29:3–14. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tuschl T, Zamore PD, Lehmann R, et al:
Targeted mRNA degradation by double-stranded RNA in vitro. Genes
Dev. 13:3191–3197. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schiffelers RM, Ansari A, Xu J, et al:
Cancer siRNA therapy by tumor selective delivery with
ligand-targeted sterically stabilized nanoparticle. Nucleic Acids
Res. 32:e1492004. View Article : Google Scholar
|
|
24
|
Weihua Z, Tsan R, Huang WC, et al:
Survival of cancer cells is maintained by EGFR independent of its
kinase activity. Cancer Cell. 13:385–393. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tan Y, Sun X, Xu M, et al: Efficacy of
recombinant methioninase in combination with cisplatin on human
colon tumors in nude mice. Clin Cancer Res. 5:2157–2163.
1999.PubMed/NCBI
|
|
26
|
Bruyere C, Lonez C, Duray A, et al:
Considering temozolomide as a novel potential treatment for
esophageal cancer. Cancer. 117:2004–2016. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang H, Che O, Chen S, et al: Silence of
VEGFR2 expression mediated by PEI/siRNA complexes. Yao Xue Xue Bao.
45:576–581. 2010.(In Chinese).
|
|
28
|
Dvorak HF: Tumors: wounds that do not
heal. Similarities between tumor stroma generation and wound
healing. N Engl J Med. 315:1650–1659. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murukesh N, Dive C and Jayson GC:
Biomarkers of angiogenesis and their role in the development of
VEGF inhibitors. Br J Cancer. 102:8–18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nyberg P, Xie L and Kalluri R: Endogenous
inhibitors of angiogenesis. Cancer Res. 65:3967–3979. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ohsaki Y, Tanno S, Fujita Y, et al:
Epidermal growth factor receptor expression correlates with poor
prognosis in non-small cell lung cancer patients with p53
overexpression. Oncol Rep. 7:603–607. 2000.PubMed/NCBI
|
|
34
|
Wu W, Onn A, Isobe T, et al: Targeted
therapy of orthotopic human lung cancer by combined vascular
endothelial growth factor and epidermal growth factor receptor
signaling blockade. Mol Cancer Ther. 6:471–483. 2007. View Article : Google Scholar
|
|
35
|
Slaton JW, Perrotte P, Inoue K, et al:
Interferon-alpha-mediated down-regulation of angiogenesis-related
genes and therapy of bladder cancer are dependent on optimization
of biological dose and schedule. Clin Cancer Res. 5:2726–2734.
1999.PubMed/NCBI
|
|
36
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hanahan D, Bergers G and Bergsland E: Less
is more, regularly: metronomic dosing of cytotoxic drugs can target
tumor angiogenesis in mice. J Clin Invest. 105:1045–1047. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jain RK: Antiangiogenic therapy for
cancer: current and emerging concepts. Oncology (Williston Park).
19:7–16. 2005.PubMed/NCBI
|
|
39
|
Higgins KJ, Abdelrahim M, Liu S, et al:
Regulation of vascular endothelial growth factor receptor-2
expression in pancreatic cancer cells by Sp proteins. Biochem
Biophys Res Commun. 345:292–301. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hobel S, Koburger I, John M, et al:
Polyethylenimine/small interfering RNA-mediated knockdown of
vascular endothelial growth factor in vivo exerts anti-tumor
effects synergistically with Bevacizumab. J Gene Med. 12:287–300.
2010.
|
